On this page
Indian consumer brands target GLP-1 users with collagen, protein and beauty products
Indian beauty, nutrition and consumer brands are developing collagen, protein, fibre and skincare products for GLP-1 drug users. Tata Consumer plans foods and beverages, while Nestle Health Science-Dr. Reddy’s has launched Celevida GLP+.
The numbers
Figures from ET Small Business,
- Next 60 days
Why it matters for the brand
Partnerships or acquisitions in clinical nutrition, functional ingredients and evidence-led beauty could help incumbents build faster credibility in the nascent GLP-1 ecosystem.
What to track next
- Growth in GLP-1 prescriptions, obesity-clinic visits and local availability of lower-cost GLP-1 therapies or generics.
- Dedicated GLP-1 nutrition shelves or search filters appearing at major pharmacy chains, marketplaces and quick-commerce platforms.
- Repeat-purchase data for protein, fibre, hydration and micronutrient products among weight-management cohorts.
- Clinician or dietitian adoption of branded nutrition protocols for GLP-1 users.
- FSSAI guidance, advertising challenges or enforcement actions related to drug-linked nutrition and weight-management claims.
Show 2 more
- Expansion of Tata Consumer, Nestlé Health Science, Dr. Reddy's and beauty players into clinically substantiated companion ranges.
- Evidence of demand shifting from aesthetics-led collagen to protein, micronutrients and muscle-preservation propositions.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Launch high-protein, high-fibre, portion-controlled foods and ready-to-drink formats designed for low appetite and digestive tolerance.
- Build pharmacy, endocrinology-clinic, dietitian and telehealth partnerships to gain recommendation-led distribution.
- Create bundles spanning protein, fibre, electrolytes, multivitamins and beauty-from-within products rather than relying on a single supplement SKU.
- Use GLP-1-adjacent language such as metabolic wellness, satiety support and muscle maintenance while maintaining substantiation and regulatory discipline.
- Monitor whether premium nutrition buyers trade out of conventional meal replacements, slimming products and mass beauty supplements.
Show 1 more
- Develop affordable sachet and small-pack formats, since sustained GLP-1 treatment costs may limit repeat purchases of premium companion products.
The counter-case
The case against this reading — not reported by the source.
The addressable market may be far smaller and less durable than the signal suggests: GLP-1 drugs remain expensive, access is limited, and many Indian users may not stay on treatment long enough to establish a distinct recurring consumption category. Products framed as GLP-1-specific can also be easily substituted by existing protein, fibre, multivitamin, hydration and skincare offerings, making differentiation weak and price premiums difficult to sustain. If brands overstate links between their products and treatment outcomes, they face credibility and regulatory risk.
The source
Published
First seen